Skip to main content

Table 5 Univariate sensitivity analysis: when the screening risk cut-off is set to 1:500 or 1:1000

From: The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis

Testing strategy 1st and 2nd trimester screening (current screening) NIPT as contingent testing
Risk 1:500 Risk 1:1000
Effectiveness
No of women undergoing 1st and 2nd trimester screening tests 66,799 66,799 66,799
No of women undergoing NIPT 0 4979 8763
No of NIPT with a positive result 0 259 264
No of ITa 3275 623 705
No of procedure-related miscarriages 23 4 5
No of T21 cases detected 271 276 281
Costs
1st and 2nd trimester screening tests €5,292,716 €5,292,716 €5,292,716
NIPT €0 €2,847,350 €5,011,600
IT €3,093,565 €588,486 €665,943
Hospitalisation due to amniotic fluid leakage and pregnancy termination owing to T21 €515,591 €482,137 €492,839
Total costs €8,901,872 €9,210,689 €11,463,098
Economic analysis NIPT as first-line testing vs 1st and 2nd trimester screening NIPT as contingent testing vs 1st and 2nd trimester screening
Risk 1:500 Risk 1:1000
Incremental cost €32,494,073 €308,817 €2,561,226
Incremental effectiveness (T21 extra cases detected) 25 5 10
ICER (€/T21 extra case detected) 1,299,763 61,763 256,123
  1. ICER, incremental cost-effectiveness ratio; IT, invasive tests; NIPT, non-invasive prenatal testing; T21, trisomy 21
  2. aOut of the total number of invasive diagnostic test performed, 271 correspond to pregnant women with a NT ≥ 3.5 mm (considered high-risk)